Outcome of Board Meeting - Submission of Unaudited Financial Results for the quarter ended on 30th September, 2025 and of Limited Review Report thereon

Revenue declinedEBITDA margin compressionNegative operating cash flowRelated-party transactionsResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-4.4%Reaction day

₹88.25

prior close

₹82.75

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.1%-4.3% vs market

Pharmaceuticals peers, median of 157sector+0.0%-4.4% vs sector

On the reaction day the stock moved 4.3 pts less than Nifty Microcap 250 and 4.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+2.7

10m

+2.7

15m

+2.7

30m

+3.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-4.4-0.1-4.3+0.0-4.4

Next day

-2.1+0.5-2.6-0.1-2.0

+0.7-0.3+1.0-0.9+1.7

+2.0-0.5+2.5-1.4+3.3

-0.3-0.8+0.5-1.6+1.3

-3.7-2.3-1.4-2.3-1.4

-3.3-2.8-0.6-2.9-0.5

15d

-2.6-4.9+2.3-3.6+1.0

-11.5-4.7-6.7-4.3-7.2

-12.7-7.7-5.0-5.6-7.1

-5.9-7.8+1.9-10.7+4.8

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Denis Chem Lab, a Gujarat-based manufacturer of parenteral (transfusion) products, reported weak Q2 FY26 numbers. Revenue from operations stood at Rs. 4,617.13 lakhs, down about 3.4% year-on-year from Rs. 4,781.76 lakhs. Profit after tax fell sharply to Rs. 221.25 lakhs (from Rs. 353.06 lakhs, a drop of around 37%), pulling EPS down to Rs. 1.60 from Rs. 2.54. For the first half, revenue was nearly flat at Rs. 8,944.72 lakhs but PAT declined around 16% to Rs. 468.75 lakhs. The auditor (Shah & Shah Associates) issued an unmodified review report with no qualifications. The company has no subsidiaries and operates in a single segment. Note: a 15% dividend (Rs. 1.50 per share, totalling Rs. 208.15 lakhs) was approved at the AGM on 26 September 2025.

Likely market impact

Negative for the stock in the near term – shrinking revenue, a steep fall in profits, and a worrying Rs. 1,148 lakh build-up in trade receivables drove operating cash flow into the red (Rs. -83.94 lakhs for H1) and forced short-term borrowings to jump from Rs. 36.73 lakhs to Rs. 753.09 lakhs. Margin compression and working-capital strain are the key risks to track; the clean auditor report is a small positive.